Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,472 total articles
Kodiak Sciences is a clinical-stage retinal biotech whose shares ripped to a 52-week high in April then dropped sharply. Fundamentals show the pipeline - especially tarcocimab - moving into late-stage programs and supporting potential regulatory filings across multiple indications. The market has punished the stock hard; at the current $34.80 price…
Bel Fuse's upsized $399M equity offering at $266 per share looked like a refashioned buyback in reverse: management sold stock at a premium, then deployed proceeds to pay down debt and close accretive deals (Enercon, dataMate). With $73M of free cash flow, a $3.6B market cap and clear M&A runway, this is a tactical long with a defined entry, stop a…
MoonLake Immunotherapeutics has a binary pipeline headline in sonelokimab, but the bull case doesn't require clinical dominance — only regulatory acceptance and a commercially viable label. With recent FDA nods, solid Week 40 Phase 3 signals in hidradenitis suppurativa (HS), a $200M offering that thickens the cash runway, and elevated short interes…
Hercules Capital (HTGC) currently trades at roughly a 45% premium to implied book value while offering a ~9.1% dividend yield and a market cap of $3.31B. We believe that durable venture lending originations, recent big-ticket financings and an improving technical setup justify paying up for HTGC. This trade plan targets $21.50 over a 180-trading-da…
Hasbro's Wizards of the Coast franchise is materially changing the growth profile of the company. With Magic: The Gathering and Dungeons & Dragons powering double-digit segment growth, Hasbro's current valuation - roughly $12.7B market cap and mid-teens P/E - looks vulnerable to a positive re-rating if execution holds. This trade idea buys into tha…
WesBanco (WSBC) trades at attractive multiples (P/E ~12, P/B ~1.02) with a healthy dividend ($0.38 quarterly) and strong free cash flow. We recommend a long trade sized to risk appetite with entry at $41.01, stop at $37.00 and target at $47.00 over a long-term horizon (180 trading days). The thesis rests on solid profitability and capital returns; …
KBR is a play on durable government/defense revenues, proprietary sustainable-process technology, and an upcoming spin-off (Trinzic) that should unlock value. At roughly $36.71 today, KBR trades at ~11x EPS with a $4.6B market cap and $23B backlog. We outline a long trade with concrete entry, targets and stop, horizon, and clear risks.
Novartis dropped sharply after pelacarsen failed its Phase III goal. The headline is painful, but the company’s $284B market cap, $9.7B free cash flow, low leverage and a diversified portfolio - including radioligand therapy exposure - provide a foundation to absorb two near-term setbacks. This trade idea outlines a disciplined long entry, stop, an…
Nebius has delivered eye-popping revenue growth and headline AI cloud deals, but the stock will be driven in the coming months by how quickly the company can convert contracted power into deployed capacity and actual billable revenue. With a market cap of roughly $64.8B and improving technicals, NBIS looks actionable on a mid-term trade that leans …
Trex (TREX) looks like a name the market punished too far after last year's revenue miss. Fundamentals still show healthy cash flow, low leverage and a defensible market position in composite decking. I like a tactical long into $46 with a mid-term target at $55, stop at $42 — trade horizon ~45 trading days.
Oracle has been punished after a heavy investment cycle in AI infrastructure that pushed free cash flow negative. The business, however, still generates predictable software economics—17% revenue growth and 77% cloud infrastructure growth reported recently—and trades at a valuation that already reflects risk. This trade buys the pullback around $16…
Insmed has delivered a strong commercial launch with Brinsupri and still trades well below its prior highs. The company carries execution risk and a premium valuation (P/S ~24x), but current weakness near $123 offers a clear risk-reward for disciplined longs. This trade idea lays out an entry, stop and a 180-trading-day target tied to continued ado…
Corcept has moved from clinical binary risk to commercial execution after FDA clearance for Lifyorli and a raised revenue outlook. The stock is no bargain — trading at P/E >200 and EV/sales near 14x — but the concrete revenue pathway and solid free cash flow create a tradeable asymmetric opportunity for disciplined long exposure with strict risk co…
Ouster trades at a premium multiple despite negative profitability, sizable cash burn, and stretched valuation metrics. Recent partner wins and product qualifications have fueled a rally, but the numbers - negative EPS, negative free cash flow, EV/sales >12 and weak returns on capital - argue for a mean reversion. This trade idea recommends a short…
ON Semiconductor ($ON) plunged on the $7B Synaptics deal but fundamentals and cashflow remain healthy. Valuation now discounts long-term upside from physical-AI exposure. This trade targets a re-rating as integration milestones and synergy delivery validate the strategic move.
Brookfield Infrastructure (BIP) is scheduled to convert to a single public corporation in Q4 2026. The move should expand the investor base, lift liquidity and index eligibility, and remove structural complexity that has kept the stock discounted. With a $24.03B market cap, a 4.8% yield and reasonable volume, the setup offers an asymmetric risk-rew…
Meta looks attractively priced for a long-term directional trade. At roughly $619 per share, the company combines a dominant social ad franchise, improving profitability metrics and $40.98B in free cash flow with a P/E near 23 and an enterprise value of $1.639T. Technicals show bullish momentum and a manageable short-interest backdrop. The trade id…
Celestica (CLS) is benefiting from a hyperscaler AI build-out that looks set to accelerate into 2027. Strong profitability (ROE ~45%), expanding AI-related revenue, and a market cap near $40.5B support a long trade with defined entry, stop, and target. Valuation is rich on headline multiples but reasonable when you factor in an outsized 2027 margin…
Tractor Supply (TSCO) has sold off sharply from its 52-week high, trading at roughly $35 with a market cap near $18.2B. Fundamentals - a large loyalty base, consistent dividend track record, positive EPS and solid return on equity - argue this is a cyclical reset rather than a broken business. This trade idea lays out an actionable long entry at $3…
CoreWeave claims roughly $100 billion of backlog that would transform its addressable revenue runway. Yet credit markets are pricing in disappointment: bonds tied to the company trade at deep discounts and implied yields that suggest lenders doubt revenue conversion and margin sustainability. This trade idea buys the equity on the expectation that …
Block (SQ) is executing on a multi-vertical fintech play that combines seller payments, Cash App consumer finance, and bitcoin exposure. We view the current setup as a buy for a tactical long: the firm's ecosystem effects and multiple monetization levers support above-consensus growth over the next 6 months, but platform consolidation and regulator…
Chevron's Project Kilby and expanded Venezuela footprint create a clear, near-term earnings and cash-flow kicker for CVX. With a market cap near $412B, P/E ~20, and free cash flow of roughly $27B, Chevron can absorb project buildout risk while returning capital to shareholders. This trade targets that re-rating over the next 45 trading days with a …
Air France-KLM ADS (AFLYY) trades at a compelling valuation - market cap roughly $3.45B and a trailing PE near 2.8 - but near-term visibility is poor. Geopolitical disruptions, integration risk from the planned SAS takeover, and seasonal/fuel dynamics make the stock a neutral play. We outline a tactical long with clear entry, stop and target for tr…
AMD is positioned to capture accelerating AI and datacenter spending through competitive CPU and GPU stacks plus FPGA/SoC integration. This trade idea recommends a long entry at $120.00 with a $200.00 target and a $95.00 stop, tailored for a long-term horizon (180 trading days). Key catalysts include next-gen accelerator ramps, enterprise CPU share…
Affirm’s Q4 beat and the rapid ramp in card adoption (5.2M active cardholders; 19% attach) make the company’s Card Engine the most tangible pathway yet to sustainable, high-margin payments profit. Valuation (~$24.4B market cap; EPS $5.72) leaves room for multiple expansion if management hits its FY27 GMV > $64B and 30.5%+ adjusted operating margin …
